These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18647813)

  • 1. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis.
    Horwitz KB; Sartorius CA
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3295-8. PubMed ID: 18647813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
    Li CI; Malone KE; Porter PL; Weiss NS; Tang MT; Cushing-Haugen KL; Daling JR
    JAMA; 2003 Jun; 289(24):3254-63. PubMed ID: 12824206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk in women receiving estrogen-progestin replacement therapy.
    Persson I
    Maturitas; 1996 May; 23 Suppl():S37-45. PubMed ID: 8865138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.
    Campagnoli C; Clavel-Chapelon F; Kaaks R; Peris C; Berrino F
    J Steroid Biochem Mol Biol; 2005 Jul; 96(2):95-108. PubMed ID: 15908197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
    Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
    JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestins and breast cancer.
    Eden J
    Am J Obstet Gynecol; 2003 May; 188(5):1123-31. PubMed ID: 12748456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy, progesterone and progestins in relation to breast cancer risk.
    Campagnoli C; Abbà C; Ambroggio S; Peris C
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):441-50. PubMed ID: 16249080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk.
    Horwitz KB
    Mol Endocrinol; 2008 Dec; 22(12):2743-50. PubMed ID: 18845670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
    Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
    Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.
    Birrell SN; Butler LM; Harris JM; Buchanan G; Tilley WD
    FASEB J; 2007 Aug; 21(10):2285-93. PubMed ID: 17413000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer and post-menopausal hormone therapy.
    Kenemans P; Bosman A
    Best Pract Res Clin Endocrinol Metab; 2003 Mar; 17(1):123-37. PubMed ID: 12763516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.